Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Brain Neoplasms 3Recurrence 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Squamous Cell 2Squamous Cell Carcinoma of Head and Neck 1Skin Squamous Cell Cancer 1Rare Tumor 1Penile Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1NSCLC 1Lung Neoplasms 1Carcinoma 1Advanced Gastric Cancer 1

Interventions

Pemetrexed 4pembrolizumab 3Ramucirumab 2Gemcitabine 2Carboplatin 2vistusertib 1vandetanib 1tusamitamab ravtansine 1telomerase reverse transcriptase p572Y, human 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1Vinorelbine 1LY3023414 1Injections 1Immune Checkpoint Inhibitors 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Cisplatin 1Bevacizumab 1AZD4547 1AZD 8931 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non-small Cell Lung Cancer Metastatic × dacomitinib × Clear all
NCT04504071 2025-09-08

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Shanghai Chest Hospital

Phase 2 Active not recruiting
30 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡